U.K. firm Kontron goes into receivership

Article

U.K. ultrasound and patient monitoring firm Kontron Instruments has gone into receivership, according to the administrator of its accounts, international accounting firm KPMG. KPMG attributed the company's failure to the reduction in healthcare spending

U.K. ultrasound and patient monitoring firm Kontron Instruments has gone into receivership, according to the administrator of its accounts, international accounting firm KPMG. KPMG attributed the company's failure to the reduction in healthcare spending in Europe, 1998's downturn in the Asian market, and increased competition in the overall healthcare market. Watford, U.K.-based Kontron reported revenues of about $24 million for the 12 months ended June 30, 1997.

The company's assets include intellectual property rights to its monitoring products, an electronic assembly plant and its machinery, raw materials, and stock. KPMG seeks to sell Kontron as a going concern and expects to find a buyer shortly, according to Paul Jeffery, administrative receiver for KPMG in Hertfordshire, U.K. Kontron owes roughly $8 million to its 450 creditors.

Recent Videos
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
Related Content
© 2025 MJH Life Sciences

All rights reserved.